AHA GUIDELINES Bundle (free trial)

High Blood Pressure - Merck Supported

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1539869

Contents of this Issue

Navigation

Page 44 of 87

45 Daily frequency Comments 2 or 3 ese are associated with sodium and water retention and reflex tachycardia and should be used with a diuretic and beta blocker. Hydralazine is associated with a drug-induced lupus-like syndrome at higher doses. Minoxidil is associated with hirsutism and requires a loop diuretic. Minoxidil can induce pericardial effusion. 1–2 1 Associated with mild-to-moderate fluid retention usually occurring within the first 4 to 6 weeks of therapy. Indicated as add-on therapy for patients whose BP is not adequately controlled on other antihypertensive medications. Avoid use in pregnancy. 5.2.4. Choice of Initial Monotherapy Versus Initial Combination Drug Therapy COR LOE Recommendations 1 B-R 1. In adults with stage 2 hypertension (SBP ≥140 mm Hg and DBP ≥90 mm Hg ), initiation of antihypertensive drug therapy with 2 first-line agents of different classes, ideally in a single-pill combination (SPC), is recommended to improve BP control and adherence. 2a C-EO 2. In adults with stage 1 hypertension (SBP 130 to 139 mm Hg and DBP 80 to 89 mm Hg ), initiation of antihypertensive drug therapy with a single first-line antihypertensive drug is reasonable, with dosage titration and sequential addition of other agents as needed to achieve BP control. 3: Harm A 3. In adults with hypertension, simultaneous use of an ACEi, ARB, and/or renin inhibitor in combination is not recommended due to the potential for harm.

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - High Blood Pressure - Merck Supported